The Grift Is The New Function

American institutions are not failing. They are functioning. The difference matters because the cure for failure is reform and the cure for functioning is reclassification. The public has been told for twenty years that the system is broken. The system is not broken. The system has acquired a new customer and is serving that customer with striking efficiency.

Consider defense procurement. The canonical description is that American military acquisitions are slow, expensive, plagued by cost overruns, and stuck producing weapons designed for the last war. Every part of that is true at the surface. Every part of it is also priced. A five-year interceptor contract with cost overruns in the tens of percent and margins to match is not a failure. It is a transfer. The institution that exists to convert tax revenue into battlefield capacity has quietly become an institution that exists to convert tax revenue into contractor equity. Both products are produced. The first is the public narrative. The second is the actual output.

Consider healthcare administration. The American healthcare system is described as an inefficient giant, pricing opaque, outcomes middle-of-the-pack for the developed world, cost-per-capita the highest on earth. This reads as failure. It is not failure. It is a revenue architecture in which opacity is the product. Every additional intermediary between patient and care converts friction into billing. The system is not designed to produce health; it is designed to produce billable events. Measured against that actual objective, it is one of the highest-performing institutions in modern history.

Consider federal regulatory capture. The narrative is that regulators have been captured by the industries they oversee, resulting in weak enforcement, revolving doors, and a rules regime written by the regulated. The narrative treats this as a pathology. It is not a pathology. It is the intended function for the second customer. A regulator that enforces against its industry produces uncertainty; uncertainty is expensive; the cost of uncertainty falls on the regulated. A captured regulator produces certainty; certainty is cheap; the value of that certainty capitalises into the regulated industry’s share price. The capture is not the corruption of the institution. It is the new function of the institution.

The word “decline” is what this frame is working against. Decline implies a direction of travel from a peak to a trough, implies a choice to restore or relinquish, implies a sense that what the country used to have was real and what it is becoming is less. None of that maps to what the evidence shows. The country is not in decline. The country is in commercialisation. The institutions that used to produce public goods are still producing outputs at scale; the outputs are simply now private.

Once the frame shifts from decline to commercialisation, the political argument shifts with it. A decline argument asks how to restore. A commercialisation argument asks who is buying, what they are paying, and what they get. Those are the questions the business press asks about any private enterprise. They are the right questions to ask of a public institution that has acquired a private customer without changing its masthead.

The hedge becomes the structure. Every major American institution is now priced as if its commercialisation is permanent. Defense contractors price their order books on the assumption that cost overruns are the floor, not the ceiling. Hospital chains price acquisitions on the assumption that administrative bloat will continue and the bloat is the product. Law firms price partnership tracks on the assumption that regulatory capture is durable and capturing regulators is a billable practice. The market has priced in what the public discourse still treats as an open question.

This is the architecture the American Series maps. Grift for the conversion itself, the quiet repricing of an institution from public utility to private revenue stream. Rift for what the commercialisation fractures as the public that funded the institution discovers it has been sold a different product than the one it paid for. Gift for the asymmetric upside that accrues to the buyer who was at the table when the re-pricing was negotiated. Drift for how a country navigates when its institutions no longer steer but still demand fuel. Shift for what arrives next, what replaces the commercialised forms, and whether the replacement is a restoration or a new round of the same operation under different branding.

The essays on this site examine one institution at a time. The novels examine what it is like to live inside the system that results. Both are reading the same evidence. Both arrive at the same verdict.

American institutions are not failing. They are functioning. The question is whose.